Drug to Treat Underlying Causes of Alzheimer's Gets EU Marketing Approval
By Connor Hart
A drug that targets an underlying cause of Alzheimer's disease being commercialized by Eisai and Biogen has received marketing approval from the European Commission.
The companies said Tuesday that the approval makes the therapy, lecanemab, the first of its kind to be granted a marketing approval in the European Union. The approval applies to all 27 EU member states, as well as Iceland, Liechtenstein and Norway.
Lecanemab is indicated to treat certain adult patients with mild cognitive impairment and dementia due to Alzheimer's disease, the company said.
"The approval of lecanemab by the European Commission marks the thirteenth approval of this important medicine, which has already benefited thousands of patients in the United States, Japan and other regions of the world," Biogen Chief Executive Christopher Viehbacher said.
Write to Connor Hart at [email protected]